COMP <GO>
CRMD vs ACRS // GROSS PROFIT MARGIN
CorMedix Inc. (NASDAQ) VS. Aclaris Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CRMD 9
— ACRS 0
▲ GROSS PROFIT MARGIN LEADER: CRMD
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
gross-margins
88.50%
LAST: $3.99 (+0.76%) • MKT CAP: $587.3M
gross-margins
73.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. ACRS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRMD | ACRS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 88.50% | 73.30% | +15.20 | CRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 45.50% | -35.00% | +80.50 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -8.04% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 48.20% | -60.00% | +108.20 | CRMD | /operating-margins <GO> |
| Net Profit Margin | 52.30% | -60.00% | +112.30 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -58.20% | +238.20 | CRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.81 | 0.20 | +1.61 | CRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.6 | 46.1 | +4.50 | CRMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $595.5M | $587.3M | $8.2M | CRMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRMD REV | ACRS REV | CRMD GROSS % | ACRS GROSS % | CRMD FCF | ACRS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.7M | $7.8M | 88.5% | 73.3% | $172.8M | -$47.2M |
| FY 2024 | $43.5M | $18.7M | 92.7% | 85.1% | -$50.7M | -$20.2M |
| FY 2023 | $0 | $31.2M | — | — | -$38.4M | -$78.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
ACRS // BETA —